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THE AGE OF INNOVATION IN FOOD: IS OUR REGULATORY
SYSTEM READY?
DEEPTI A. KULKARNI *
The United States is at the epicenter of a revolution in food innovation
and food culture. Innovators are finding new ways to produce food more
efficiently and with fewer impacts on our environment, using emerging and
advanced technologies such as genome editing, synthetic biology, and animal
cell culture technology. Consumer interests and expectations continue to
rapidly evolve, and many consumers are looking for healthier, more
sustainable, and diverse alternatives. At the same time, the world’s
population is growing exponentially and is estimated to reach over nine
billion people in the next thirty years 1—meaning, we will have to produce
more food, more efficiently, and with a much smaller footprint.
Against this backdrop, regulatory agencies are determining how to
facilitate innovation that addresses many of these and other challenges, while
protecting human health and the environment, and assuring that foods are
appropriately labeled and otherwise compliant with current law. 2
Furthermore, it is expected that there will be a “profusion of new products”
that could “overwhelm the U.S. regulatory system” within the next decade. 3
Is our current regulatory system ready?
To answer this question, one must revisit the primary federal statutes
governing foods, most of which were enacted over half a century ago,
evaluate whether and how these laws can be effectively applied to new and
emerging products, and then assess whether the current regulatory system
does just that. Indeed, in a recent report by the National Academies of
© 2021 Deepti A. Kulkarni
* Deepti A. Kulkarni is 2008 graduate of the University of Maryland Francis King Carey School
of Law and a partner in the Food, Drug, and Medical Device Regulatory Practice Group at Sidley
Austin, LLP. She thanks Jaclyn Fonteyne for her helpful contributions to this Essay.
1. World Population Prospects 2019: Highlights, UNITED NATIONS DEP’T OF ECON. & SOC.
AFFAIRS 1 (2019), https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf.
2. See, e.g., Dennis Keefe, FDA In Brief: FDA approves soy leghemoglobin as a color
additive, FDA (July 31, 2019), https://www.fda.gov/news-events/fda-brief/fda-brief-fda-approvessoy-leghemoglobin-color-additive (“We are in the midst of a revolution in food technology that in
the next 10 years will likely lead to more innovations in food and ingredient production than there
have been in the past half century. As these new products and ingredient sources come to the market,
the FDA has a responsibility to provide the appropriate regulatory oversight to protect public health
by ensuring that these new foods and food ingredients are safe.”).
3. NAT’L ACADS. OF SCIS., ENG’G, AND MED., PREPARING FOR FUTURE PRODUCTS OF
BIOTECHNOLOGY ix, 10 (2017).
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Sciences, Engineering, and Medicine (“NASEM”)—addressing new types of
biotechnology products and evaluation of these products under current
regulatory frameworks—NASEM advised that the safe use of such products
“requires rigorous, predictable, and transparent risk-analysis processes
whose comprehensiveness, depth, and throughput mirror the scope, scale,
complexity, and tempo of future biotechnology applications.” 4 Such an
approach, according to NASEM, also would increase “public confidence in
the safety of products entering the marketplace.” 5 NASEM cautioned that a
regulatory paradigm “that is unnecessarily complex runs the risk of driving
an ‘imitate not innovate’ mentality and may not scale to match the pace of
biotechnology innovation.” 6
The NASEM report was commissioned by the federal regulatory
agencies with primary oversight of products developed using biotechnology,
as part of a wide-ranging initiative to modernize the U.S. regulatory system
that began in July 2015. 7 These agencies include the Food and Drug
Administration (“FDA”), Department of Agriculture (“USDA”), and
Environmental Protection Agency (“EPA”). The federal regulatory policy
describing the statutory authorities of each agency and how such authorities
are applied to biotechnology products, particularly foods, is known as the
Coordinated Framework for the Regulation of Biotechnology (“Coordinated
Framework”). 8
First established in 1986, and subsequently updated in 1992 and 2017,
the Coordinated Framework describes the roles and responsibilities of FDA,
USDA, and EPA in the regulation of biotechnology products under existing
statutory authorities 9 and sets forth key principles for the regulation of such
4.
5.
6.
7.

Id. at 11.
Id.
Id.
John P. Holdren, Administrator, Office of Information and Regulatory Affairs to Heads of
the
FDA,
EPA,
and
USDA
(July
2,
2015),
https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/modernizing_the_reg_sys
tem_for_biotech_products_memo_final.pdf.; see also Modernizing the Regulatory System for Plant
and Animal Biotechnology Products, FDA (last updated Sept. 12, 2018),
https://www.fda.gov/safety/fdas-regulation-plant-and-animal-biotechnologyproducts/modernizing-regulatory-system-plant-and-animal-biotechnology-products.
8. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302, (June 26,
1986); see also About the Coordinated Framework, UNIFIED WEBSITE FOR BIOTECHNOLOGY
REGULATION, https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/about
(last
visited Feb. 28, 2021).
9. See generally Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg.
23,302 (June 26, 1986); Exercise of Federal Oversight Within Scope of Statutory Authority:
Planned Introductions of Biotechnology Products Into the Environment, 57 Fed. Reg. 6753 (Feb.
27, 1992); EXEC. OFFICE OF THE PRESIDENT, MODERNIZING THE REGULATORY SYSTEM FOR
BIOTECHNOLOGY PRODUCTS: FINAL VERSION OF THE 2017 UPDATE TO THE COORDINATED
FRAMEWORK
FOR
THE
REGULATION
OF
BIOTECHNOLOGY
(2017),
https://www.fda.gov/media/102658/download [hereinafter 2017 Update].
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products. 10 Under the Coordinated Framework, FDA regulates foods
developed using biotechnology to “[e]nsure human and animal food is safe”
and “properly labeled” pursuant to its expansive authority under the Federal
Food, Drug, and Cosmetic Act (“FDCA”). 11 Historically, the vast majority
of these foods have been derived from genetically engineered (“GE”) plants
and microorganisms. FDA also has evaluated foods derived from GE
animals, though to date has only approved two applications relating to such
foods. 12 There are multiple statutes identified in the Coordinated Framework
under which USDA, in theory, could exercise oversight relating to foods
developed using biotechnology. Consistent with the actual use of
biotechnology to develop foods, USDA, to date, primarily has regulated GE
plants, particularly food crops, deemed “plant pests” pursuant to the agency’s
interpretation and authority under the Plant Protection Act (“PPA”), “with a
goal of protecting plants and plant products.” 13 EPA generally has oversight
10. The key principles set forth in the Coordinated Framework serve as guidance for FDA,
USDA, and EPA to help ensure the safety of biotechnology products. These principles provide, in
relevant part, that: (1) each agency should apply its existing authorities “to ensure the safety of []
biotechnology products for their intended applications;” (2) “[u]nderlying statutes define the
boundaries of the scope of oversight afforded to each agency;” (3) the agencies should apply their
authorities to “regulate products based upon specific uses” to assure that “products with the same
use are subject to the same types of [regulatory] oversight;” (4) “[i]t is the characteristics of the
biotechnology product, the environment into which it will be introduced, and the application of the
product that determine its risk (or lack thereof);” (5) “[e]xercise of agency oversight within the
scope afforded by statutes should be commensurate with the risk posed” by the biotechnology
product “and should not turn on the fact that it was created or has been altered by a particular process
or technique;” (6) the regulatory system should be “risk-based;” (7) the agencies should “endeavor
to operate their programs in an integrated and coordinated” manner; and (8) future scientific
developments should “lead to further refinements of the Coordinated Framework . . . to reflect a
more complete understanding of the potential risks involved.” 2017 Update at 7–8.
11. Id. at 9. Notably, however, in 2016, Congress passed the National Bioengineered Food
Disclosure Standard (“Disclosure Standard”), which directs USDA, rather than FDA, to establish a
national disclosure standard for bioengineered foods, as defined in the law. Pub. L. No. 114-216,
130 Stat. 834 (2016) (codified as amended at 7 U.S.C. § 1639). USDA’s Agricultural Marketing
Service promulgated regulations implementing the Disclosure Standard in 2018. See National
Bioengineered Food Disclosure Standard, 83 Fed. Reg. 65,814 (Dec. 21, 2018).
12. See Animals with Intentional Genomic Alterations, FDA (last updated Dec. 14, 2020),
https://www.fda.gov/animal-veterinary/biotechnology-products-cvm-animals-and-animalfood/animals-intentional-genomic-alterations. In November 2015, FDA approved a new animal
drug application (NADA) concerning AquAdvantage Salmon, Atlantic salmon genetically
engineered to reach market size “more rapidly that its non-GE farm-raised Atlantic salmon
counterpart.”
AquAdvantage Salmon Fact Sheet, FDA (last updated Apr. 15, 2020),
https://www.fda.gov/animal-veterinary/animals-intentional-genomic-alterations/aquadvantagesalmon-fact-sheet. In December 2020, FDA approved an NADA for a “first-of-its-kind intention
genomic alteration (IGA) in a line of domestic pigs, referred to as GalSafe pigs, which may be used
for food or human therapeutics.” FDA Approves First-of-its-Kind Intentional Genomic Alteration
in Line of Domestic Pigs for Both Human Food, Potential Therapeutic Uses, FDA (last updated
Dec. 14, 2020), https://www.fda.gov/news-events/press-announcements/fda-approves-first-itskind-intentional-genomic-alteration-line-domestic-pigs-both-human-food.
13. See 2017 Update, supra note 9 at 23–24.
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of pesticides produced through biotechnology, including those produced in
food crops, pursuant to the Federal Insecticide, Fungicide, and Rodenticide
Act (“FIFRA”), with the goal of protecting the environment and human
health. 14
Will these multiple and often overlapping federal regulatory statutes
enable regulators to appropriately address the anticipated “profusion of new
products” in a manner that facilitates critically important innovations? 15 The
short answer, of course, is that it depends. The statutes, themselves broadly
define and encompass foods 16 and potential technologies that may be used to
modify plants, microbes, and animals to develop foods, 17 or otherwise
address potential risks arising from the development and commercialization
of such foods. 18 Accordingly, the statutory authorities should provide ample
authority for comprehensive oversight. The question, thus, is whether the
regulatory agencies have implemented policies pursuant to these authorities
to appropriately regulate new products based upon risk and the best available

14. See id. at 10–11.
15. See NAT’L ACADS. OF SCIS., ENG’G, AND MED., supra note 3, at ix.
16. For example, under the FDCA, “food” is defined to mean “(1) articles used for food or drink
for man or other animals, (2) chewing gum, and (3) articles used for components of any such
article.” 21 U.S.C. § 321(f). “Food additives,” which are subject to FDA premarket review, are
defined in relevant part as “any substance the intended use of which results or may reasonably be
expected to result, directly or indirectly, in its becoming a component or otherwise affecting the
characteristics of any food (including any substance intended for use in producing, manufacturing,
packing, processing, preparing, treating, packaging, transporting, or holding food,” unless generally
recognized as safe (“GRAS”) or otherwise exempt. Id. § 321(s).
17. For example, FDA takes the position that “[s]ubstances that are expected to become
components of food products as a result of genetic modification of a plant and whose composition
is such or has been altered such that the substance is not generally recognized as safe (GRAS) or
otherwise exempt are subject to regulation as ‘food additives’” under the FDCA. Statement of
Policy: Foods Derived from New Plant Varieties, 57 Fed. Reg. 22,984, 22,984–85 (May 29, 1992).
Within the context of animals, FDA currently asserts that the use of genetic engineering or gene
editing to modify an animal is subject to FDA’s new animal “drug” authorities. See CVM GFI #187
Regulation of Intentionally Altered Genomic DNA in Animals, FDA (last updated Sept. 18, 2018),
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-187regulation-intentionally-altered-genomic-dna-animals. In particular, FDA considers the “altered
genomic DNA” of the animal to be a “drug” within the meaning of the FDCA “because such altered
DNA is an article intended to affect the structure or function of the body of the animal, and, in some
cases, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in the
animal.” Id. at 7; see also 21 U.S.C. § 321(g) (defining a “drug” within the meaning of the FDCA).
18. For example, foods containing “unsafe” food additives, pesticide chemical residues, or new
animal drugs, which in theory could include foods developed using biotechnology, are prohibited
from introduction into interstate commerce and subject to various civil and criminal penalties under
the FDCA. See 21 U.S.C. §§ 343(a)(2), 331(a), 332, 333, 334. In addition, the Plant Protection Act
of 2000 (“PPA”) grants USDA the authority to prevent the introduction or control the dissemination
of plant pests in the United States. 7 U.S.C. § 7711(a). Using this authority, USDA’s APHIS
regulates certain genetically engineered plants as “plant pests” and requires review and permitting
for movement of such products in interstate commerce. Movement of Certain Genetically
Engineered Organisms, 85 Fed. Reg. 29,790 (May 18, 2020).
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science and in a manner that is coordinated, predictable, efficient, and
scalable. 19
In some areas, the agencies have taken steps toward implementing such
policies. For example, in May 2020, USDA’s Animal and Plant Health
Inspection Service (“APHIS”) published a long-awaited final rule, amending
its regulation of GE organisms under the PPA. 20 The amendments, among
other things, seek to focus APHIS’s approach to protecting plant health, spur
innovation, and facilitate the availability of new crop varieties that are safe
for plant health and not currently marketed, such as more sustainable
varieties, or those with improved nutrient profiles. 21 While the new
regulations are still being implemented, the amendments indicate movement
in a promising direction. Another example is oversight of animal cell culture
technology. After a purported “turf battle” between FDA and USDA, 22 the
agencies issued a joint agreement in March 2019, announcing that they will
jointly oversee such products, pursuant to longstanding and relatively wellunderstood policies and relevant expertise. 23 Although there are a number of
open questions remaining, including those relating to requirements for
labeling and inspection, the joint agreement provides much-needed clarity on
the overarching regulatory framework for these products and generally has
been embraced by a wide range of stakeholders. 24
In other areas, however, there remains significant uncertainty or lack of
clarity. One example is the regulatory paradigm for GE animals, which is in
a state of flux. On January 19, 2021, the last day of the Trump
Administration, the U.S. Department of Health and Human Services finalized
19. See Holdren, supra note 7; NAT’L ACADS. OF SCIS., ENG’G, AND MED., supra note 3, at 11;
see also Modernizing the Regulatory System for Plant and Animal Biotechnology Products, supra
note 7.
20. Movement of Certain Genetically Engineered Organisms, 85 Fed. Reg. 29,790 (May 18,
2020).
21. See About the SECURE Rule, USDA (last updated Feb. 19, 2021),
https://www.aphis.usda.gov/aphis/ourfocus/biotechnology/biotech-rule-revision
(providing
information and answers about the SECURE Rule).
22. See, e.g., Helena Bottemiller Evich, Welcome to the turf battle over lab-grown meat,
POLITICO (June 15, 2018 6:12 PM), https://www.politico.com/story/2018/06/15/lab-grown-meatfeds-turf-battle-629774.
23. See USDA and FDA Announce a Formal Agreement to Regulate Cell-Cultured Food
Products from Cell Lines of Livestock and Poultry, USDA (Mar. 7, 2019),
https://www.usda.gov/media/press-releases/2019/03/07/usda-and-fda-announce-formalagreement-regulate-cell-cultured-food; Formal Agreement Between FDA and USDA Regarding
Oversight of Human Food Produced Using Animal Cell Technology Derived from Cell Lines of
USDA-amenable Species, FDA (Mar. 7, 2019), https://www.fda.gov/food/domestic-interagencyagreements-food/formal-agreement-between-fda-and-usda-regarding-oversight-human-foodproduced-using-animal-cell.
24. See, e.g., USDA, FDA finalize cultured meat regulatory agreement, AGRI-PULSE (Mar. 7,
2019 2:12 PM), https://www.agri-pulse.com/articles/11978-usda-fda-finalize-cultured-meatregulatory-agreement (discussing positive reactions to the agreement from various stakeholders).
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a “Memorandum of Understanding” (“MOU”) with USDA, shifting
regulatory responsibility for certain GE animals intended for food and other
agricultural purposes from FDA to USDA. 25 In response, then-FDA
Commissioner, Dr. Stephen Hahn, maintained that “FDA does not support
the Memorandum of Understanding” and “has no intention of abdicating [its]
public health mandate. 26 His predecessor, Dr. Scott Gottlieb, also denounced
the MOU, calling it “an unprecedented usurping of FDA public health
authority,” and calling for FDA to continue to “regulate animal biotech as
part of its [public health] mandate.” 27 The Biden Administration has yet to
articulate a clear position on its view of the MOU. Notably, however, on
March 8, 2021, APHIS reopened the comment period for an Advance Notice
of Proposed Rulemaking (“ANPR”), originally published in late 2020 before
the release of the MOU, that proposes a framework for oversight governed
by USDA rather than FDA, pursuant to USDA’s statutory authorities under
the Animal Health Inspection Act, Federal Meat Inspection Act, and Poultry
Product Inspection Act. 28 By reopening the comment period, the Biden
Administration has signaled that it will consider overhauling the regulatory
framework for GE animals as set forth in the ANPR, thereby indicating that
the debate over regulatory reform will rage on. Another example is FDA’s
approach to foods derived from genome-edited plants. In early 2017, FDA
requested comments on the use of genome editing techniques to produce new
plant varieties for human and animal foods and its approach to oversight. 29
In October 2018, FDA announced its intent to “develop guidance for industry
explaining how [its] current regulatory policy for foods derived from new
plant varieties applies to foods produced using genome editing” and to update
its existing procedures “to reflect the FDA’s 25 years of experience with
foods derived from biotechnology plants.” 30 Although a draft version of this
guidance appears to have been under review by the Office of Management
and Budget (“OMB”) during the final days of the Trump Administration, it

25. See Memorandum of Understanding Between the United States Department of Agriculture
and the Food and Drug Administration, Department of Health and Human Services, FDA & USDA
(Jan 13, 2021), https://www.aphis.usda.gov/biotechnology/downloads/mou-usda-fda.pdf; Secretary
Perdue Statement on MOU on Animal Biotechnology, USDA (Jan. 19, 2021),
https://www.usda.gov/media/press-releases/2021/01/19/secretary-perdue-statement-mou-animalbiotechnology.
26. Stephen M. Hahn (@SteveFDA), TWITTER (Jan. 19, 2021 2:45 PM),
https://twitter.com/SteveFDA/status/1351616813705154562.
27. Scott Gottlieb (@ScottGottliebMD), TWITTER (Jan. 19, 2021 3:08 PM),
https://twitter.com/scottgottliebmd/status/1351622618647027713.
28. 86 Fed. Reg. 13,221 (Mar. 8, 2021); 85 Fed. Reg. 84,269 (Dec. 28, 2020).
29. Genome Editing in New Plant Varieties Used for Foods; Request for Comments, 82 Fed.
Reg. 6564 (Jan. 19, 2017).
30. FDA, PLANT AND ANIMAL BIOTECHNOLOGY INNOVATION ACTION PLAN 5 (Oct. 2018),
https://www.fda.gov/media/119882/download.
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was subsequently withdrawn from OMB review and, to date, has not been
finalized. 31
Thus, the regulatory landscape is highly evolving and still taking new
shape. There are signs indicating that the agencies are adapting their
regulatory frameworks, based on existing law, science, and experience, to
better address new products, but much remains to be seen and the revolution
seems far from over.

31. See, e.g., Beth Wang, OMB Withdraws 6 FDA Regs, Guides, FDA Yanks Tobacco Rules,
INSIDE HEALTHPOLICY (Jan. 22, 2021 6:21 PM), https://insidehealthpolicy.com/daily-news/ombwithdraws-6-fda-regs-guides-fda-yanks-tobacco-rules.

